SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>NORBY R DOUGLAS</u> 09/19/2017		3. Issuer Name and Ticker or Trading Symbol <u>Krystal Biotech, Inc.</u> [KRYS]					
		4. Relationship of Reporting Perso (Check all applicable) X Director Officer (give title	on(s) to Issuer 10% Owner Other (specify		5. If Amendment, Date of Original Filed (Month/Day/Year) 09/19/2017		
		below)	below)`	í e	Applicable Line) X Form filed by	/Group Filing (Check y One Reporting Person y More than One erson	
Table I - Non-Derivative Securities Beneficially Owned							
1. Title of Security (Instr. 4)						ature of Indirect Beneficial Ownership r. 5)	
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)							
2. Date Exercisable and Expiration Date (Month/Day/Year)			y (Instr. 4) Conve or Exe		ise Form:	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
Date Exercisable	Expiratior Date	n Title	Amount or Number of Shares	Derivative Security	/e or Indirect		
11/30/2020 ⁽¹⁾	11/29/2026	6 Common Stock	18,949	2.46(2	²⁾ D		
	Requiring State (Month/Day/Yea 09/19/2017 Table I - Nor Table II - I e.g., puts, cal 2. Date Exercisable Date Exercisable	Requiring Statement (Month/Day/Year) 09/19/2017 Table I - Non-Deriva Table II - Derivative e.g., puts, calls, warra 2. Date Exercisable and Expiration Date (Month/Day/Year) Date Exercisable Expiration Date Date Exercisable Expiration Date	Requiring Statement (Month/Day/Year) Krystal Biotech, Inc. 09/19/2017 4. Relationship of Reporting Perse (Check all applicable) X Director Officer (give title below) Officer (give title below) Table I - Non-Derivative Securities Beneficially 2. Amount of Securities Beneficially Owned (Instr. 4) Table II - Derivative Securities Beneficially e.g., puts, calls, warrants, options, convertible 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Securities Date Expiration Date Title	Requiring Statement (Month/Day/Year) Krystal Biotech, Inc. [KRYS] 09/19/2017 4. Relationship of Reporting Person(s) to Issue (Check all applicable) X Director 10% Owne Officer (give title below) Other (spec- below) Table I - Non-Derivative Securities Beneficially Owned (Instr. 5) 3. Ownersh Form: Direc or Indirect ((Instr. 5) Table II - Derivative Securities Beneficially Owned e.g., puts, calls, warrants, options, convertible securities (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Securities (Instr. 4) Date Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Securities Shares Amount or Number of Shares	Requiring Statement (Month/Day/Year) Krystal Biotech, Inc. [KRYS] 09/19/2017 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director Officer (give title Other (specify below) Table I - Non-Derivative Securities Beneficially Owned Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) Table II - Derivative Securities Beneficially Owned e.g., puts, calls, warrants, options, convertible securities (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) Date Expiration Date Title Amount of Shares Amount of Shares	Requiring Statement (Month/Day/Year) Krystal Biotech, Inc. [KRYS] 09/19/2017 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) 5. If Amendment, Da (Month/Day/Year) X Director 10% Owner Officer (give title below) Other (specify below) 6. Individual or Joint Applicable Line) X Form filed b Form filed b Reporting P Table I - Non-Derivative Securities Beneficially Owned (Instr. 5) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect (Instr. 5) Table II - Derivative Securities Beneficially Owned e.g., puts, calls, warrants, options, convertible securities (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	

Explanation of Responses:

1. The options were awarded on November 30, 2016 and vest ratably over a four-year period.

2. The exercise price was incorrectly reported in the reporting person's original Form 3, filed September 19, 2017.

Remarks:

<u>/s/ Katherine A. Shaia, as</u>

attorney-in-fact for R. Douglas 09/25/2017 Norby

<u>INOIDy</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.